A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio) in Patients With De Novo Lesions of the Native Coronary Arteries.

Trial Profile

A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio) in Patients With De Novo Lesions of the Native Coronary Arteries.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2013

At a glance

  • Drugs Paclitaxel; Pimecrolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms GENESIS
  • Most Recent Events

    • 14 May 2012 Planned end date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Cordis-Corporation added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top